Key result
Tirzepatide shows up to ~29% weight loss and improved HbA1c in post-gastrectomy weight regain.
Why the study?
Some patients experience weight regain and worsening of T2DM after laparoscopic sleeve gastrectomy, prompting evaluation of tirzepatide in this setting.
Does tirzepatide improve weight and glycemic control in patients with obesity-associated T2DM experiencing weight regain after laparoscopic sleeve gastrectomy?
Case Report (n=3)
Does tirzepatide improve weight and glycemic control in patients with obesity-associated T2DM experiencing weight regain after laparoscopic sleeve gastrectomy?
Tirzepatide may be an effective therapeutic option for managing weight regain and suboptimal glycemic control in patients after metabolic bariatric surgery, potentially delaying the need for revisional surgery.
May support tirzepatide for post-LSG weight regain and glycemic control; leaves open efficacy and practice change pending prospective trials.
Background: Laparoscopic sleeve gastrectomy is an effective metabolic surgery; however, some patients experience weight regain and worsening of type 2 diabetes mellitus (T2DM) over the long term. Tirzepatide (TZP), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated potent weight loss and glucose-lowering effects. This study evaluated the clinical outcomes of TZP treatment in patients facing weight regain and insufficient glycemic control after LSG. Methods and results: We performed a retrospective clinical analysis of three male patients with obesity-associated T2DM who developed significant weight regain and suboptimal glycemic control several years after undergoing LSG. Despite repeated nutritional counseling and behavioral modification, their conditions remained refractory. Following the initiation of weekly TZP treatment, all three patients achieved substantial weight reduction and significant improvements in HbA1c levels. Specifically, Case 1 achieved a total weight loss (%TWL) of 14.0% from the pre-LSG baseline (13.2% weight loss specifically from TZP initiation) over 12 months. Case 2 achieved a %TWL of 13.2% from the pre-LSG baseline (8.5% weight loss from TZP initiation) over 6 months. Case 3 achieved a %TWL of 27.3% from the pre-LSG baseline (28.7% weight loss from TZP initiation) over 9 months. Notably, all patients reached HbA1c levels below 6.0% (range: 5.2%-5.6%), surpassing the glycemic control achieved in the immediate postoperative period. TZP was well-tolerated, with only mild constipation reported as an adverse event. Conclusion: TZP may serve as a promising therapeutic option for managing weight regain and insufficient glycemic control in patients after metabolic bariatric surgery, potentially delaying or eliminating the need for complex revisional surgery.
No takes yet. Share an insight, caveat, or question.
Fujishiro et al. (2026) conducted a case report in Obesity-associated type 2 diabetes (n=3). Tirzepatide was evaluated on Weight reduction and HbA1c levels. Weekly tirzepatide treatment in three patients with weight regain after sleeve gastrectomy resulted in 8.5% to 28.7% weight loss and HbA1c reductions to below 6.0% over 6 to 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: